Medical outcome of renal allograft donors at National kidney transplant center-Saint Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia

  • Seyfemichael Getachew

Abstract

Introduction: Chronic kidney disease (CKD) is defined as the presence of one or more markers of kidney damage for greater than 3 months. If not treated, it leads to other complications and decreased quality of life. The global burden of CKD is increasing accompanied by increase in need of kidney transplantation increasing the number of living donors in parallel. Studies show that kidney donation has a medical risk to the donor showing difference based on varying demographics. In Ethiopia there is no previous study regarding donor’s risk of medical complication.

Objectives: To assess medical outcome of renal allograft donors at the national kidney transplant center- Saint Paul’s Hospital Millennium Medical College (SPHMMC), Addis Ababa, Ethiopia.

Methods: A hospital based retrospective chart review study was conducted at SPHMMC among 43 kidney donors who were on follow up from September 2015 to August 2018. Data was collected using pretested data abstraction tool. Epi-Info version 7.2.1.0 was used for data entry and SPSS version 23.0 and STATA version 14.1 were used analysis.

Results: Median duration of follow up was 12 months. The incidence rate of CKD and hypertension among the donors during the three years observation period was on average 4.1 per 100 person years of observation and 8.2 per 100 person years of observation respectively.

 

Key words: Renal allograft donor, medical outcome, retrospective chart review, survival analysis, Ethiopia

References

1. Kumar P, clark M. Kumar and Clark Clinical Medicine. 6th ed2014. 248-58 p.
2. Fauci A, Braunwald E, Kasper D. Harrison Principles of Internal Medicine 18th edn ed. New York NY: McGraw Hill Medical; 2015.
3. Wang H, Naghavi M, Allen C, al e. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study. Lancet 2016;388:1459-544.
4. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72.
5. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States 2015. Available from: http://www.cdc.gov/ckd.
6. Samar AE, Davide B, Graziella D, Evangelia D, Giovanni T, Carmine Z. Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: a systematic review. BMJ. 2107;8(1).
7. John WS, Bocheng J, Scott T, et al. The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. 2014;2(3):174-81.
8. Temesgen F, Mehidi K, Tilahun Y. Prevalence of Chronic Kidney Disease and Associated Risk Factors among Diabetic Patients in Southern Ethiopia. American Journal of Health Research. 2014;2(4):216-21.
9. Gabriel MD. Handbook of renal transplant 6th ed: LWW; 2017. 624 p.
10. Horvat LD, Shariff SZ, Garg AX, the Donor Nephrectomy Outcomes Research (DONOR) Network. Global trends in the rates of living kidney donation. Kidney Int. 2009;75(10):1088–98.
11. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major non communicable diseases. Kidney Int. 2011;80(12):1258-70.
12. Bal MM, Saikia B. Gender bias in renal transplantation: are women alone donating kidneys in India? Transplant Proc. 2007;39:2961-63.
13. O’Keeffe LM, Ramond A, Oliver W, et al. Mid- and long-term health risks in living kidney donors. Ann Internal Med. 2018;168(4):276-84.
14. Kasiske BL. Outcomes after living kidney donation: what we still need to know and why. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2014;64(3):335-7.
15. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med. 2009;360(5):459-69.
16. Reisaeter AV, Roislien J, Henriksen T, Irgens LM, Hartmann A. Pregnancy and birth after kidney donation: the Norwegian experience. Am J Transplant. 2009;9(4):820–24.
17. R. W. Steiner, J. H, D. E. Rifkin, B. Gert. Estimating Risks of De Novo Kidney Diseases After Living Kidney Donation. American Journal of Transplantation. 2014;14:538-44.
18. Muzaale AD, Massie AB, Wang MC, et al. Risk of end-stage renal disease following live kidney donation. JAMA. 2014;311(6):579–86.
19. Morgan EG, Yingying S, Andrew SL, et al. Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. N Engl J Med. 2016;374:411-21.
20. Mjoen G, Hallan S, Hartmann A, et al. Long-term risks for kidney donors. Kidney Int. 2014;86(1):162-7.
21. Krista LL, Anita P. Risks and Outcomes of Living Donation. Adv Chronic Kidney Dis. 2102;19(4):220–8.
22. Grams ME, Sang Y, Levey AS, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016;374:411-21.
23. Bryce AK, Karthik KT. Lifetime risks of kidney donation: a medical decision analysis. BMJ Renal medicine research. 2017;7(8).
24. Allan B, Massie, Abimereki D, et al. Quantifying Post donation Risk of ESRD in Living kidney donors. Journal of the American Society of Nephrology. 2017.
25. Federal Demcratic Republic of Ethiopian MoH. Health and Health Related Indicators. . Addis Ababa, Ethiopia: 2016.
26. KIDGO. Clinical Guideline for Evaluation and Management of Chronic Kidney Disease. 2nd ed2012.
27. JNC 8. Hypertension Guideline Algorithm2014.
28. Richard J, John F, Jurgen F. Comprehensive Clinical Nephrology. 5th ed2014.
29. The American College of Obstetricinas and Gynecologists. Clinical Management Guidelines for Obstetrician-Gynacologists. ACOG Practice Bulletin2013.
30. American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes. Diabetes Care. 2018;2018(41):S13–S27.
31. Karen AH, H M James H, Kenneth WM, al e. Draft Definition for CDISC2014.
Published
2020-03-30